RNAC Q4 2022 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RNACCartesian Therapeutics, Inc.

$218M

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$17M-43.9% YoY

Gross Profit

$16M96.4% margin

Operating Income

-$8M-50.6% margin

Net Income

$6M35.1% margin

EPS (Diluted)

$1.16

QoQ Revenue Growth

-18.9%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$166M

Total Liabilities

$72M

Stockholders' Equity

$94M

Cash & Equivalents

$106M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$17M	$30M	-43.9%
Gross Profit	$16M	$30M	-45.9%
Operating Income	-$8M	$4M	-308.3%
Net Income	$6M	$12M	-51.9%